학술논문

Aberrant type 1 immunity drives susceptibility to mucosal fungal infections
Document Type
article
Source
Science. 371(6526)
Subject
Autoimmune Disease
Emerging Infectious Diseases
Infectious Diseases
2.1 Biological and endogenous factors
Aetiology
Infection
Inflammatory and immune system
Adolescent
Adult
Aged
Animals
Candida albicans
Candidiasis
Chronic Mucocutaneous
Disease Models
Animal
Female
Humans
Immunity
Mucosal
Immunologic Surveillance
Interferon-gamma
Interleukins
Janus Kinases
Male
Mice
Mice
Inbred BALB C
Middle Aged
Mouth Mucosa
Polyendocrinopathies
Autoimmune
Receptors
Interleukin-17
STAT1 Transcription Factor
T-Lymphocytes
Young Adult
Genomics and Computational Biology Core
General Science & Technology
Language
Abstract
Human monogenic disorders have revealed the critical contribution of type 17 responses in mucosal fungal surveillance. We unexpectedly found that in certain settings, enhanced type 1 immunity rather than defective type 17 responses can promote mucosal fungal infection susceptibility. Notably, in mice and humans with AIRE deficiency, an autoimmune disease characterized by selective susceptibility to mucosal but not systemic fungal infection, mucosal type 17 responses are intact while type 1 responses are exacerbated. These responses promote aberrant interferon-γ (IFN-γ)- and signal transducer and activator of transcription 1 (STAT1)-dependent epithelial barrier defects as well as mucosal fungal infection susceptibility. Concordantly, genetic and pharmacologic inhibition of IFN-γ or Janus kinase (JAK)-STAT signaling ameliorates mucosal fungal disease. Thus, we identify aberrant T cell-dependent, type 1 mucosal inflammation as a critical tissue-specific pathogenic mechanism that promotes mucosal fungal infection susceptibility in mice and humans.